Subscribe to RSS
DOI: 10.1055/a-2749-2763
Role of Platelets in Abdominal Aortic Aneurysm Formation and Progression: New Aspects from Experimental and Clinical Approaches
Authors
Funding The study was supported by the Deutsche Forschungsgemeinschaft (DFG), grant number EL651/6-1 (Project number: 440966856) and Collaborative Research Centre TRR259 (Aortic Disease, Project number: 397484323) to M.E.
Abstract
Abdominal aortic aneurysm (AAA) is a vascular disease with an atherosclerotic background resulting in progressive abdominal aortic dilation. The mechanisms of AAA progression include chronic inflammation within the aneurysm segment, reinforcing extracellular matrix degradation, and weakening of the aortic vessel wall. Platelets are essential mediators of hemostasis and play a dominant role in cardiovascular disease. Recent data suggest a pivotal role of platelets in AAA formation and progression by dysregulated platelet activation. These findings include a potential crosstalk of platelets with different cell types such as macrophages and fibroblasts, which amplifies the inflammatory response within the aortic tissue and promotes aortic wall stiffening. Experimental studies provided evidence for platelets to directly contribute to AAA formation and progression via the collagen receptor glycoprotein VI by promoting vascular inflammation, as well as aortic wall remodeling. Moreover, platelet and red blood cell interactions via the TSP-1–CD36 axis reinforces aneurysm formation via elevated procoagulant activity of both cells in experimental mice and AAA patients. Therefore, platelets and a platelet-mediated cellular crosstalk play a crucial role in AAA by promoting the development and progression of AAA. To date, no therapeutic treatment is available and surgical repair is the only option to prevent patients from aortic rupture. Thus, there is a strong need for an effective therapy to attenuate AAA progression. This review highlights the mechanisms of platelet activation and the relevance for the identification of new platelet-derived targets to develop a drug-based therapy for AAA patients.
* Contributed equally.
Publication History
Received: 30 October 2025
Accepted: 17 November 2025
Article published online:
19 February 2026
© 2026. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011; 25 (04) 155-167
- 2 Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev 2015; 29 (03) 153-162
- 3 Tian Y, Zong Y, Pang Y. et al. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther 2025; 10 (01) 159
- 4 Gowert NS, Donner L, Chatterjee M. et al. Blood platelets in the progression of Alzheimer's disease. PLoS One 2014; 9 (02) e90523
- 5 Lebas H, Yahiaoui K, Martos R, Boulaftali Y. Platelets are at the nexus of vascular diseases. Front Cardiovasc Med 2019; 6: 132
- 6 Shaik NF, Regan RF, Naik UP. Platelets as drivers of ischemia/reperfusion injury after stroke. Blood Adv 2021; 5 (05) 1576-1584
- 7 Reusswig F, Polzin A, Klier M. et al. Only acute but not chronic thrombocytopenia protects mice against left ventricular dysfunction after acute myocardial infarction. Cells 2022; 11 (21) 3500
- 8 Reusswig F, Dille M, Krüger E. et al. Platelets modulate cardiac remodeling via the collagen receptor GPVI after acute myocardial infarction. Front Immunol 2024; 14: 1275788
- 9 Klose AM, Klier M, Gorressen S, Elvers M. Enhanced integrin activation of PLD2-deficient platelets accelerates inflammation after myocardial infarction. Int J Mol Sci 2020; 21 (09) 3210
- 10 Feige T, Bosbach A, Krott KJ. et al. GP VI-mediated platelet activation and procoagulant activity aggravate inflammation and aortic wall remodeling in abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2024; 44 (11) 2294-2317
- 11 Sun W, Zheng J, Gao Y. Targeting platelet activation in abdominal aortic aneurysm: current knowledge and perspectives. Biomolecules 2022; 12 (02) 206
- 12 Wagenhäuser MU, Mulorz J, Krott KJ. et al. Crosstalk of platelets with macrophages and fibroblasts aggravates inflammation, aortic wall stiffening, and osteopontin release in abdominal aortic aneurysm. Cardiovasc Res 2024; 120 (04) 417-432
- 13 Sakalihasan N, Michel JB, Katsargyris A. et al. Abdominal aortic aneurysms. Nat Rev Dis Primers 2018; 4 (01) 34
- 14 Vorp DA, Mandarino WA, Webster MW, Gorcsan III J. Potential influence of intraluminal thrombus on abdominal aortic aneurysm as assessed by a new non-invasive method. Cardiovasc Surg 1996; 4 (06) 732-739
- 15 Didangelos A, Yin X, Mandal K. et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011; 10 (08) 008128
- 16 Lederle FA, Johnson GR, Wilson SE. et al; Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann Intern Med 1997; 126 (06) 441-449
- 17 Di Achille PTG, Figueroa CA, Humphrey JD. A haemodynamic predictor of intraluminal thrombus formation in abdominal aortic aneurysms. Royal Society 2014; 470 (2172) 20140163
- 18 Linden MD. Platelet physiology. Methods Mol Biol 2013; 992: 13-30
- 19 Fredrickson BJ, Dong JF, McIntire LV, López JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998; 92 (10) 3684-3693
- 20 Chatterjee M, Ehrenberg A, Toska LM. et al. Molecular drivers of platelet activation: unraveling novel targets for anti-thrombotic and anti-thrombo-inflammatory therapy. Int J Mol Sci 2020; 21 (21) 7906
- 21 Krott KJ, Feige T, Elvers M. Flow chamber analyses in cardiovascular research: impact of platelets and the intercellular crosstalk with endothelial cells, leukocytes, and red blood cells. Hamostaseologie 2023; 43 (05) 338-347
- 22 Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28 (03) 403-412
- 23 Gale AJ. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol 2011; 39 (01) 273-280
- 24 Clemetson KJ. Platelets and primary haemostasis. Thromb Res 2012; 129 (03) 220-224
- 25 Klatt C, Krüger I, Zey S. et al. Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. J Clin Invest 2018; 128 (09) 3906-3925
- 26 Krott KJ, Feige T, Elvers M. Platelet-red blood cell interactions. In: Gresele P, López JA, Angiolillo DJ, Page CP. eds. Platelet Physiology II and Laboratory Testing: Volume 2. Springer Nature Switzerland; 2025: 721-739
- 27 Martinez Bravo G, Annarapu G, Carmona E. et al. Platelets in thrombosis and atherosclerosis: a double-edged sword. Am J Pathol 2024; 194 (09) 1608-1621
- 28 Szymańska P, Luzak B, Siarkiewicz P, Golański J. Platelets as potential non-traditional cardiovascular risk factor-analysis performed in healthy donors. Int J Mol Sci 2023; 24 (19) 14914
- 29 Baidildinova G, Nagy M, Jurk K, Wild PS, Ten Cate H, van der Meijden PEJ. Soluble platelet release factors as biomarkers for cardiovascular disease. Front Cardiovasc Med 2021; 8: 684920
- 30 Yan C, Wu H, Fang X, He J, Zhu F. Platelet, a key regulator of innate and adaptive immunity. Front Med (Lausanne) 2023; 10: 1074878
- 31 Nicolai L, Pekayvaz K, Massberg S. Platelets: orchestrators of immunity in host defense and beyond. Immunity 2024; 57 (05) 957-972
- 32 Huang J, Li X, Shi X. et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol 2019; 12 (01) 26
- 33 Wang L, Liu Y, Tian R. et al. What do we know about platelets in myocardial ischemia-reperfusion injury and why is it important?. Thromb Res 2023; 229: 114-126
- 34 Schanze N, Hamad MA, Nührenberg TG, Bode C, Duerschmied D. Platelets in myocardial ischemia/reperfusion injury. Hamostaseologie 2023; 43 (02) 110-121
- 35 Krott KJ, Reusswig F, Dille M. et al. Platelets induce cell apoptosis of cardiac cells via FasL after acute myocardial infarction. Biomedicines 2024; 12 (05) 1077
- 36 Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat Rev Cardiol 2019; 16 (04) 225-242
- 37 O'Leary SA, Kavanagh EG, Grace PA, McGloughlin TM, Doyle BJ. The biaxial mechanical behaviour of abdominal aortic aneurysm intraluminal thrombus: classification of morphology and the determination of layer and region specific properties. J Biomech 2014; 47 (06) 1430-1437
- 38 Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol 2018; 81: 241-330
- 39 Jana S, Hu M, Shen M, Kassiri Z. Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm. Exp Mol Med 2019; 51 (12) 1-15
- 40 Satta J, Juvonen T, Haukipuro K, Juvonen M, Kairaluoma MI. Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples. J Vasc Surg 1995; 22 (02) 155-160
- 41 Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. Atherosclerosis 1987; 65 (1-2): 13-21
- 42 López-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997; 150 (03) 993-1007
- 43 Davis V, Persidskaia R, Baca-Regen L. et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998; 18 (10) 1625-1633
- 44 Thompson RW, Holmes DR, Mertens RA. et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96 (01) 318-326
- 45 Pyo R, Lee JK, Shipley JM. et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105 (11) 1641-1649
- 46 Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998; 102 (11) 1900-1910
- 47 Eskandari MK, Vijungco JD, Flores A, Borensztajn J, Shively V, Pearce WH. Enhanced abdominal aortic aneurysm in TIMP-1-deficient mice. J Surg Res 2005; 123 (02) 289-293
- 48 Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122 (02) 264-271 , discussion 271–272
- 49 Quintana RA, Taylor WR. Cellular mechanisms of aortic aneurysm formation. Circ Res 2019; 124 (04) 607-618
- 50 Puchenkova OA, Soldatov VO, Belykh AE. et al. Cytokines in abdominal aortic aneurysm: master regulators with clinical application. Biomark Insights 2022;17:11772719221095676
- 51 Miller Jr FJ, Sharp WJ, Fang X, Oberley LW, Oberley TD, Weintraub NL. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol 2002; 22 (04) 560-565
- 52 Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006; 26 (05) 987-994
- 53 Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004; 114 (02) 300-308
- 54 Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31 (05) 453-463
- 55 Li H, Bai S, Ao Q. et al. Modulation of immune-inflammatory responses in abdominal aortic aneurysm: emerging molecular targets. J Immunol Res 2018; 2018: 7213760
- 56 Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of abdominal aortic aneurysm. Front Immunol 2022; 13: 989933
- 57 Michel JB, Martin-Ventura JL, Egido J. et al; FAD EU consortium. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 2011; 90 (01) 18-27
- 58 Plana E, Oto J, Medina P, Fernández-Pardo Á, Miralles M. Novel contributions of neutrophils in the pathogenesis of abdominal aortic aneurysm, the role of neutrophil extracellular traps: a systematic review. Thromb Res 2020; 194: 200-208
- 59 Eliason JL, Hannawa KK, Ailawadi G. et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation 2005; 112 (02) 232-240
- 60 Yan H, Zhou HF, Akk A. et al. Neutrophil proteases promote experimental abdominal aortic aneurysm via extracellular trap release and plasmacytoid dendritic cell activation. Arterioscler Thromb Vasc Biol 2016; 36 (08) 1660-1669
- 61 Houard X, Touat Z, Ollivier V. et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82 (03) 532-541
- 62 Cohen JR, Parikh S, Grella L. et al. Role of the neutrophil in abdominal aortic aneurysm development. Cardiovasc Surg 1993; 1 (04) 373-376
- 63 Eilenberg W, Zagrapan B, Bleichert S. et al. Histone citrullination as a novel biomarker and target to inhibit progression of abdominal aortic aneurysms. Transl Res 2021; 233: 32-46
- 64 Ibrahim N, Bleichert S, Klopf J. et al. Reducing abdominal aortic aneurysm progression by blocking neutrophil extracellular traps depends on thrombus formation. JACC Basic Transl Sci 2024; 9 (03) 342-360
- 65 Papapanagiotou A, Daskalakis G, Siasos G, Gargalionis A, Papavassiliou AG. The role of platelets in cardiovascular disease: molecular mechanisms. Curr Pharm Des 2016; 22 (29) 4493-4505
- 66 Cameron SJ, Russell HM, Owens III AP. Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?. Blood 2018; 132 (25) 2619-2628
- 67 Piechota-Polanczyk A, Jozkowicz A, Nowak W. et al. The abdominal aortic aneurysm and intraluminal thrombus: current concepts of development and treatment. Front Cardiovasc Med 2015; 2: 19
- 68 Boyd AJ. Intraluminal thrombus: innocent bystander or factor in abdominal aortic aneurysm pathogenesis?. JVS Vasc Sci 2021; 2: 159-169
- 69 Wilson JS, Virag L, Di Achille P, Karsaj I, Humphrey JD. Biochemomechanics of intraluminal thrombus in abdominal aortic aneurysms. J Biomech Eng 2013; 135 (02) 021011
- 70 Ma X, Xia S, Liu G, Song C. The detrimental role of intraluminal thrombus outweighs protective advantage in abdominal aortic aneurysm pathogenesis: the implications for the anti-platelet therapy. Biomolecules 2022; 12 (07) 942
- 71 Haller SJ, Crawford JD, Courchaine KM. et al. Intraluminal thrombus is associated with early rupture of abdominal aortic aneurysm. J Vasc Surg 2018; 67 (04) 1051-1058.e1
- 72 Hansen KB, Arzani A, Shadden SC. Mechanical platelet activation potential in abdominal aortic aneurysms. J Biomech Eng 2015; 137 (04) 041005
- 73 Milne AA, Adam DJ, Murphy WG, Ruckley CV. Effects of asymptomatic abdominal aortic aneurysm on the soluble coagulation system, platelet count and platelet activation. Eur J Vasc Endovasc Surg 1999; 17 (05) 434-437
- 74 Erdem Yaman A, Poyraz E. Antiplatelet or anticoagulant therapy for abdominal aortic aneurysms: growth and clinical outcomes. Anatol J Cardiol 2024; 28 (04) 187-193
- 75 Busch A, Bleichert S, Ibrahim N. et al. Translating mouse models of abdominal aortic aneurysm to the translational needs of vascular surgery. JVS Vasc Sci 2021; 2: 219-234
- 76 Lu G, Su G, Davis JP. et al. A novel chronic advanced stage abdominal aortic aneurysm murine model. J Vasc Surg 2017; 66 (01) 232-242.e4
- 77 Owens III AP, Edwards TL, Antoniak S. et al. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2015; 35 (09) 2032-2041
- 78 Morrell CN, Mix D, Aggarwal A. et al. Platelet olfactory receptor activation limits platelet reactivity and growth of aortic aneurysms. J Clin Invest 2022; 132 (09) e152373
- 79 Benson TW, Pike MM, Spuzzillo A. et al. Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target. Blood 2024; 144 (16) 1663-1678
- 80 Liu O, Jia L, Liu X. et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One 2012; 7 (12) e51707
- 81 Kay JG, Grinstein S. Phosphatidylserine-mediated cellular signaling. Adv Exp Med Biol 2013; 991: 177-193
- 82 Noh JY, Lim KM, Bae ON. et al. Procoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid. Am J Physiol Heart Circ Physiol 2010; 299 (02) H347-H355
- 83 Peyrou V, Lormeau JC, Hérault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 1999; 81 (03) 400-406
- 84 Whelihan MF, Mann KG. The role of the red cell membrane in thrombin generation. Thromb Res 2013; 131 (05) 377-382
- 85 Krott KJ, Feige T, Bosbach A. et al. Interplay between thrombospondin-1 and CD36 modulates platelet-RBC interaction in thrombosis and abdominal aneurysm formation. Circ Res 2025;
- 86 Pachel C, Mathes D, Arias-Loza AP. et al. Inhibition of platelet GPVI protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2016; 36 (04) 629-635
- 87 Wichaiyo S, Parichatikanond W, Rattanavipanon W. Glenzocimab: a GPVI (glycoprotein VI)-targeted potential antiplatelet agent for the treatment of acute ischemic stroke. Stroke 2022; 53 (11) 3506-3513
- 88 Bigalke B, Stellos K, Weig HJ. et al. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 2009; 104 (03) 352-357
- 89 Bigalke B, Haap M, Stellos K. et al. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 2010; 125 (05) e184-e189
- 90 Mazighi M, Köhrmann M, Lemmens R. et al; ACTIMIS Study Group. Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial. Lancet Neurol 2024; 23 (02) 157-167
- 91 Uphaus T, Richards T, Weimar C. et al. Revacept, an inhibitor of platelet adhesion in symptomatic carotid stenosis: a multicenter randomized phase II trial. Stroke 2022; 53 (09) 2718-2729
- 92 Boulaftali Y, Mawhin MA, Jandrot-Perrus M, Ho-Tin-Noé B. Glycoprotein VI in securing vascular integrity in inflamed vessels. Res Pract Thromb Haemost 2018; 2 (02) 228-239
- 93 Burkard P, Schonhart C, Vögtle T. et al. A key role for platelet GPVI in neutrophil recruitment, migration, and NETosis in the early stages of acute lung injury. Blood 2023; 142 (17) 1463-1477
- 94 Aburima A, Berger M, Spurgeon BEJ. et al. Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets. Blood 2021; 137 (05) 678-689
- 95 Gayen Betal S, Setty BN. Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain. Transl Res 2008; 152 (04) 165-177
- 96 Kuijpers MJ, de Witt S, Nergiz-Unal R. et al. Supporting roles of platelet thrombospondin-1 and CD36 in thrombus formation on collagen. Arterioscler Thromb Vasc Biol 2014; 34 (06) 1187-1192
- 97 Nergiz-Unal R, Lamers MM, Van Kruchten R. et al. Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. J Thromb Haemost 2011; 9 (09) 1835-1846
- 98 Liu Z, Morgan S, Ren J. et al. Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ Res 2015; 117 (02) 129-141
- 99 Yang H, Zhou T, Sorenson CM, Sheibani N, Liu B. Myeloid-derived TSP1 (thrombospondin-1) contributes to abdominal aortic aneurysm through suppressing tissue inhibitor of metalloproteinases-1. Arterioscler Thromb Vasc Biol 2020; 40 (12) e350-e366
- 100 Touat Z, Ollivier V, Dai J. et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168 (03) 1022-1030
- 101 Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52 (01) 55-61.e2
- 102 Lindholt JS, Björck M, Michel JB. Anti-platelet treatment of middle-sized abdominal aortic aneurysms. Curr Vasc Pharmacol 2013; 11 (03) 305-313
- 103 Mohammadmoradi S, Heier K, Driehaus ER. et al. Impact of aspirin therapy on progression of thoracic and abdominal aortic aneurysms. Atherosclerosis 2025; 407: 119224
- 104 Elbadawi A, Omer M, Ogunbayo G. et al. Antiplatelet medications protect against aortic dissection and rupture in patients with abdominal aortic aneurysms. J Am Coll Cardiol 2020; 75 (13) 1609-1610
- 105 Hariri E, Matta M, Layoun H. et al. Antiplatelet therapy, abdominal aortic aneurysm progression, and clinical outcomes. JAMA Netw Open 2023; 6 (12) e2347296
- 106 Wanhainen A, Mani K, Kullberg J. et al. The effect of ticagrelor on growth of small abdominal aortic aneurysms-a randomized controlled trial. Cardiovasc Res 2020; 116 (02) 450-456
- 107 Su Z, Guo J, Gu Y. Pharmacotherapy in clinical trials for abdominal aortic aneurysms: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2022;28:10760296221120423
- 108 Gröschel K, Uphaus T, Loftus I. et al. Revacept, an inhibitor of platelet adhesion in symptomatic carotid artery stenosis: design and rationale of a randomized phase II clinical trial. TH Open 2020; 4 (04) e393-e399
